Alsheikh currently holds the MD position at Spectropharma. Alsheikh MD & Co-Founder SpectropharmaĪbdulAziz A. We are keen to work relentlessly to change the way diseases are treated, through aggressively pursuing new pathways and investing in cutting edge technologies and treatment modalities that surpass and outperform today's solutions.ĪbdulAziz A. Our constant endeavor is to look for theraphy breakthroughs wherever they occur, leveraging internal expertise and embracing external science to bring the best solutions to the pople who urgently need them. As part of this priority, we aim to collaborate with multinational suppliers, academia, governments, and society to further drive the transformation of the healthcare sector. Only then, can we deliver groundbreaking solutions to the population most in need. One of our key priorities is to advocate for sustainable healthcare system that value innovation and is accessible to people all over the world.Īs the global healthcare landscape presents new challenges, new diseases, and new dynamics, it is crucial to ensure that healthcare technology rapidly evolves to keep pace. Through working proactively with stakeholders such as governments, healthcare agencies, our suppliers, and other segments of society in specific markets, Spectropharma seeks to ensure broad and timely access to medicines. Spectropharma will forge strategic relationships, alliances, and partnerships with channel partners to maximize its reach and prevention.īy investing in cutting edge pharmaceutical technology, research and development infrastructure, technology transfer, and building upon talented human capital, Spectropharma will help local and regional health care system and patients by bringing more theraphy options with high quality standard. Spectropharma specializes in producing Biosimilars, generic pharmaceuticals, CSSD, and infection protection products through partnership with multinational companies as well as in-house development. Through a robust quality standard, state of the art technologies, and high talent pharmacist, engineers and marketers, Spectropharma would leverage its strengths to establish itself as a major player in the pharmaceutical market in KSA and across the globe. Therefore, emphasis on high quality is the essence of its brands and will help company to differentiate from the market along with affordable medicine prices to its patients. Spectropharma believes that quality is the most vital determinant of a company's reputation among commercial and institutional customers in the pharmaceutical industry. The plant was constructed and equipped up to the highest quality levels. Spectropharma manufacturing facility is in Sudair industrial city, 120KM north east of Riyadh, with a plant site that covers 54,000 sq. It is core business is development, manufacturing, and sales of pharmaceutical products in Saudi Arabia and abroad. Spectropharma is a Saudi company that was established in 2019.
0 kommentar(er)
